Empagliflozin in Patients with Chronic Kidney Disease

BACKGROUND: This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. METHODS: We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus matching placebo. Eligib...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrington, William G., Staplin, Natalie, Wanner, Christoph, Green, Jennifer B., Hauske, Sibylle J., Emberson, Jonathan R., Preiss, David, Judge, Parminder, Mayne, Kaitlin J., Ng, Sarah Y.A., Sammons, Emily, Zhu, Doreen, Hill, Michael, Stevens, Will, Wallendszus, Karl, Brenner, Susanne, Cheung, Alfred K., Liu, Zhi-Hong, Li, Jing, Hooi, Lai Seong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Maggioni, Aldo P., Pontremoli, Roberto, Deo, Rajat, Goto, Shinya, Rossello, Xavier, Tuttle, Katherine R., Steubl, Dominik, Petrini, Michaela, Massey, Dan, Eilbracht, Jens, Brueckmann, Martina, Landray, Martin J., Baigent, Colin, Haynes, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614055/
https://www.ncbi.nlm.nih.gov/pubmed/36331190
http://dx.doi.org/10.1056/NEJMoa2204233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614055/
https://www.ncbi.nlm.nih.gov/pubmed/36331190
http://dx.doi.org/10.1056/NEJMoa2204233

Ejemplares similares